
|Articles|January 13, 2010
A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study
Combination bevacizumab and 25?J/cm2 or 12?J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study aimed at examining number of treatments, but not visual acuities. However, visual acuities responded favourably in all three groups.
Advertisement
British Journal of Ophthalmology - To determine if reduced light dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over six months compared to bevacizumab monotherapy in neovascular age-related macular degeneration (AMD).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Why ST-100 is expanding from dry eye into corneal wound healing
2
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
3
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
4
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
5
















